Company / Free Cash Flow per Share
Ultragenyx Pharmaceutical Inc. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$5.10
FY2025
5-year range
-$7.39 / -$5.10
FY2021-FY2025
Trend
+0.2%
vs FY2024
Sector context
#177 of 192
Health Care
What the data says
Among 192 Health Care companies, Ultragenyx Pharmaceutical Inc. is in the bottom 8% for free cash flow per share. Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-7.39 in FY2023 to $-1.20 in FY2016.
Based on SEC 10-K filings.
-5.10 in FY2025.
Improved from $-7.39 to $-5.10 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 192This company -$5.10 Sector average -$19.84
▼
+74.3% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share increased 0.2% year-over-year.
- Ranks #177 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2016.
- Lowest free cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.10 | +0.2% |
| FY2024 | -$5.11 | +30.8% |
| FY2023 | -$7.39 | -3.2% |
| FY2022 | -$7.16 | -29.2% |
| FY2021 | -$5.54 | -8.8% |
| FY2020 | -$5.09 | -1.0% |
| FY2019 | -$5.05 | +24.4% |
| FY2018 | -$6.67 | -148.0% |
| FY2017 | -$2.69 | -123.6% |
| FY2016 | -$1.20 | +60.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026